The immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1, which have improved the outcomes of patients with various forms of advance-stage tumor, mark a landmark breakthrough in cancer treatment (1). The gene discussed is PDCD1; the disease is cancer.